A Novel NCI-H69AR Drug-Resistant Small-Cell Lung Cancer Mini-Tumor Model for Anti-Cancer Treatment Screening

Area of Science:

• Oncology
• Biotechnology
• Cancer Research

Background:

• Small-cell lung cancer (SCLC) exhibits poor prognosis and high relapse rates due to multi-drug resistance (MDR).
• Overexpression of efflux transporter proteins is a key mechanism contributing to MDR in cancer.
• Traditional 2D cell culture models lack the physiological complexity of in vivo tumors, limiting their utility in chemotherapy development.

Purpose of the Study:

• To develop and characterize a novel 3D spheroid model of drug-resistant SCLC using a rotating clinostat bioreactor.
• To evaluate the stability and physiological relevance of the 3D model for assessing anti-cancer drug efficacy.
• To investigate the model's response to standard chemotherapeutic agents and its utility in studying MDR mechanisms.

Main Methods:

• Development of a drug-resistant NCI-H69AR spheroid model using the ClinoStar® rotating clinostat bioreactor.
• Assessment of spheroid growth, viability, and metabolic stability over a 25-day period.
• Evaluation of anti-cancer drug treatment (irinotecan, paclitaxel, cisplatin) efficacy and recovery, with analysis of planar surface area, glucose consumption, protein content, ATP, adenylate kinase, histology, and gene expression.

Main Results:

• The 3D spheroid model demonstrated viability and stability during the experimental and treatment periods.
• The model retained relative hyperexpression of the MRP1 efflux transporter gene and showed increased P-gp transporter gene expression compared to 2D cultures.
• The drug-resistant mini-tumors showed minimal impact from clinical doses of irinotecan, paclitaxel, and cisplatin, with notable recovery post-treatment.

Conclusions:

• The established 3D spheroid model provides a physiologically relevant platform for studying drug-resistant SCLC.
• This model effectively mimics in vivo tumor characteristics and MDR, offering a valuable tool for chemotherapy development and drug screening.
• The model's stability and responsiveness to chemotherapeutic agents highlight its potential for advancing cancer research.